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esponsibility of InstAbstract The pharmacokinetic proﬁle of gallocatechin-7-gallate (J10688) was studied in rats after
intravenous administration. Male and female Sprague-Dawley (SD) rats received 1, 3, and 10 mg/kg (i.v.)
of J10688 and plasma drug concentrations were determined by a high performance liquid chromato-
graphy-mass spectrometry (LC–MS) method. The pharmacokinetic software Data Analysis System
(Version 3.0) was used to calculate the pharmacokinetic parameters. For different i.v. doses of J10688, the
mean peak plasma concentration (C0) values ranged from 11.26 to 50.82 mg/L, and mean area under the
concentration-time curve (AUC0–t) values ranged from 1.75 to 11.80 (mg  h/L). J10688 lacked dose-
dependent pharmacokinetic properties within doses between 1 and 10 mg/kg, based on the power model.
The method developed in this study was sensitive, precise, and stable. The pharmacokinetic properties of
J10688 in SD rats were shown to have rapid distribution and clearance values. These pharmacokinetic
results may contribute to an improved understanding of the pharmacological actions of J10688.
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Pharmacokinetic study of gallocatechin-7-gallate in rats 651. Introduction
Pithecellobium clypearia Benth., a member of Mimosaceae
family, is a well-known and widely used traditional Chinese
medicine1. It is mostly distributed in the South of China, such
as Sichuan, Yunnan and Guangdong provinces. For many years, P.
clypearia has been used in the treatment of respiratory tract
diseases2–4. It is recorded in the Chinese Pharmacopoeia 2010
that, the aqueous extract of the leaves and twigs of P. clypearia
has been used for the treatment of upper respiratory tract
infections, laryngitis, pharyngitis, acute gastroenteritis, acute
tonsillitis, and bacterial dysentery5–7. Until now, various ﬂavo-
noids have been found in P. clypearia, most of which have anti-
viral properties8. It has been conﬁrmed that aqueous extracts from
P. clypearia exhibit anti-inﬂuenza activity both in vitro and
in vivo. The cytopathic effects induced by inﬂuenza virus in cells
and pneumonia in mice were inhibited signiﬁcantly by this
aqueous extract9. (–)-Epigallocatechin-7-gallate isolated from P.
clypearia exhibited a strong inhibition on the T lymphocytes
proliferation induced by concanavalin A (ConA) with an IC50 of
4.4 μmol/L10.
Our previous study has shown that three compounds in the
ethyl acetate extract of P. clypearia exhibited inﬂuenza virus
neuraminidase inhibitory activity and anti-inﬂammatory activity
in vitro11–13. One of the potent compounds, gallocatechin-7-gallate
(J10688) (Fig. 1), a novel polyphenol ﬂavonoid with anti-inﬂuenza
viral activity11, has been selected as the candidate compound for
further research. In the previous study, we found that J10688 could
inhibit inﬂuenza virus replication in human lung adenocarcinoma
cell (A549), down-regulated the mRNA expression of inﬂuenza
hemagglutinin gene, signiﬁcantly down-regulated the inﬂuenza
viral nucleoprotein and M2 ion channel expression, and also
inhibited the secretion of inﬂammatory factors (data not pub-
lished). To better understand the pharmacological actions of
J10688, we presently performed pharmacokinetic research with
this compound.
In this study, a simple, selective, and sensitive high perfor-
mance liquid chromatography–mass spectrometry (LC–MS)
method for the quantiﬁcation of J10688 in rat plasma was
developed, and the pharmacokinetic properties of this agent were
studied after intravenous administration.2. Materials and methods
2.1. Chemicals and reagents
J10688 had been successfully separated and identiﬁed in the
previous work11. Samples puriﬁed and used presently had a purityFigure 1 The chemical structures ofof 99%. Quercetin (internal standard, IS) was purchased from the
National Institutes for Food and Drug Control (Beijing, China).
Acetonitrile (LC–MS grade), methanol (HPLC grade) were
obtained from J. T. Baker (Phillipsburg, NJ, USA), and formic
acid (HPLC grade) bought from TEDIA Company (Fairﬁeld, OH,
USA). Pure water was purchased from Wahaha Company (Hang-
zhou, China). All the other chemical reagents were of analytical
grade or higher level.
2.2. Instrumentation
The Agilent 1200 liquid chromatography-6100 mass spectrometer
was employed for data acquisition and data post-processing. The
system was equipped with G1311A quaternary gradient pump,
G1379B vacuum degasser, G1329A auto-sampler, G1316A col-
umn oven and an ESI ion source.
2.3. Chromatographic conditions
The analytical column was Agilent Zorbax SD-C18 (100 mm 2.1
mm, 3.5 μm). The mobile phase was composed of acetonitrile-water
(0.1% formic acid) (23:77, v/v). Injection volume was 20 μL, the total
run time was 12 min and the ﬂow rate was 0.3 mL/min. The column
temperature was maintained at 35 1C.
The mass spectrometer was operated in the negative scan mode.
The conditions of ESI source were as follows: drying gas ﬂow was
set at 10 L/min, drying gas temperature was 350 1C, nebulizer
pressure was 35.0 psig and capillary voltage was 3000 V. The ESI
was performed using nitrogen to assist nebulization. The typical
compound parameters, fragmentor voltage and gain value, were set
at 80 V and 1.5, respectively. The MS detector was operated in
selective ion monitoring (SIM) mode using the quantiﬁcation ions
[M–H]– at m/z 441.0 for J10688 and m/z 301.0 for quercetin (IS).
2.4. Animals
Male and female Sprague-Dawley (SD) rats of 6–8 weeks old with
weighing between 200 and 240 g were purchased from the Vital
River Lab Animal Technology Co., Ltd. (Beijing, No. SCXK
2012-0001). All animals received care according to the Guide for
the Care and Use of Laboratory Animals.
2.5. Preparation of stock solutions and standards
Primary stock solutions of J10688 and IS were prepared separately
by dissolving analytes in methanol to obtain the concentration of
1 mg/mL and stored at 40 1C. Stock solutions were diluted to
working solutions with methanol for use. Quality control (QC)(A) J10688 and (B) quercetin (IS).
Chao Li et al.66samples were prepared by spiking corresponding standard working
solutions with 135 μL of blank rat plasma at concentration of 50,
500 and 1500 ng/mL. To construct the plasma calibration curves, a
series of working standard solutions at the concentrations of 10,
50, 100, 250, 500, 1000 and 2000 ng/mL J10688 were similarly
prepared.
2.6. Preparation of plasma samples
Rat plasma (100 μL) and 10 μL of IS solution (quercetin,
500 ng/mL) were mixed, and 1000 μL ethyl acetate was added
to extract the analytes from the plasma. After vortexing for 5 min,
the mixture was centrifuged at 13,000 rpm for 10 min. Then the
supernatant was transferred into another tube carefully and
evaporated to dryness under a gentle ﬂow of nitrogen gas. The
residue was reconstituted in 50 μL 50% methanol–water solutions.
After centrifugation, the supernatant was injected into LC–MS
system for analysis.
2.7. Method validation
According to the Industrial Guidelines for Bioanalytical Method
Validation from the US FDA the current LC-MS method was
validated in biological samples of speciﬁcity, linearity, the lower
limit of quantiﬁcation (LLOQ), precision, accuracy, matrix effect,
extraction recovery and stability.
2.7.1. Speciﬁcity
The speciﬁcity of the established method was evaluated by
comparing the chromatograms of blank plasma from no less than
six individual rats with the plasma sample 20 min after intravenous
injection of J10688 and a blank rat plasma sample spiked withFigure 2 Full scan mass spectra of (A) J10688 with the m/z 441.0
[M–H]– and (B) IS with the m/z 301.0 [M–H]–.J10688 and IS. The purpose was to ensure that there is no
endogenous interference at the retention times of J10688 and IS.
2.7.2. Linearity and sensitivity
The calibration standards of J10688 were prepared by spiking
blank rat plasma with the standard solution to the concentrations
ranged 10–2000 ng/mL. Calibration curves were established by
plotting the peak area ratio of J10688 to IS (Y-axis) versus the
nominal concentration of J10688 (X-axis), and ﬁtted with by
least square weighted linear regression. The lower limit of
quantiﬁcation (LLOQ) was deﬁned as the lowest concentration
of which the detected response reaches 10-fold of signal-to-
noise ratio (10 S/N).
2.7.3. Accuracy and precision
The precision of the method was deﬁned as the relative standard
deviation (RSD) calculated from replicate measurements of QCs.
Intra-day and inter-day precision were determined by measuring
samples at three concentrations with ﬁve QC samples per level
(50, 250 and 1500 ng/mL). The accuracy of the method was
characterized as the RE (%), which was the mean of the replicate
measurements of QCs from the theoretical values. It was accep-
table when the RE (%) and RSD (%) values were less than 15%.
RE % Calculated value Theoretical value /
Theoretical value 100 1
( ) = ( − )
× ( )
2.7.4. Extraction recovery and matrix effect
Recovery was calculated by comparing the peak area obtained
from an extracted sample with that obtained from unextracted
standard solution prepared with the same solvent.
The matrix effects were determined by comparing the peak
areas obtained from samples where the extracted matrix was
spiked with standard solutions to those of the pure samples
prepared in mobile phase containing equivalent amounts of the
analyte at three concentrations.
2.7.5. Stability
The stability of J10688 in rat plasma was evaluated at three levels
of QC samples. Short-term stability was tested after QC samples
had been kept at 25 1C for 4 h. And in the long-term stability, the
QC samples were stored at 40 1C for four weeks before
detection. QC samples were also analyzed following three
freeze/thaw cycles. In each freeze/thaw cycle, the samples were
frozen for 24 h at 20 1C and thawed to ambient temperature. At
last, the processed samples were stored in the autosampler for 24 h
before analyzed. Samples were considered to be stable if the
deviation from the nominal concentration was within 715.0%.
2.8. Pharmacokinetic study
J10688 was dissolved in 60% hydroxypropyl-β-cyclodextrin pre-
pared with normal saline, vortexed until the solution became
transparent. According to the drug non-clinical pharmacokinetic
guidelines14, three dose groups (1, 3 and 10 mg/kg) had been set
up in this study. The high dose group (10 mg/kg) is the maximum
tolerated dose, and the low-dose group (1 mg/kg) is the minimum
effective dose. The middle dose group (3 mg/kg) was the
logarithmic midpoint between 10 and 1 mg/kg. After intravenous
administration of J10688, the blood samples were collected into
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0.333, 0.5, 0.75, 1, 2, 4 and 6 h postinjection. After centrifuged at
5000 rpm for 10 min, 100 μL plasma were achieved. These
samples were stored at 80 1C before analysis.
2.9. Parameters calculation
The software DAS 3.0 pharmacokinetic program (Chinese Phar-
macology Society) was used to calculate the pharmacokinetic
parameters and a non-compartment model analysis was employed.3. Results and discussion
3.1. LC–MS optimization
The chromatographic conditions were optimized through several trials
using various columns and mobile phases to achieve good chromato-
graphic separation of J10688 and IS. In this section of work, the
HPLC–DAD was employed for optimizing the chromatographic
condition. The chromatograms under the wavelengths of 280 nm
and 256 nm (Supplementary Fig. 1) were selected to monitor the drug
and internal standard, respectively. To make the LC condition
transferable to the LC–MS method, the identical HPLC instrument
was employed. Three different types and sizes of C18 columns in ourFigure 3 Typical chromatograms of J10688 and IS. (A) Blank rat plasma
and IS (50 ng/mL); (C) rat plasma sample at 60 min after intravenous injelaboratory, Eclipse Plus C18 (100 mm 2.1 mm, 3.5 μm), Eclipse
XDB C18 (150 mm 4.6 mm, 5 μm) and ZORBAX SB C18
(100 mm 2.1 mm, 3.5 μm) were selected as the candidate columns.
Different acetonitrile ratios in mobile phase ranged 20%–40% were
also investigated. As shown in Supplementary Figs. 2–4, the
ZORBAX SB C18 (100 mm 2.1 mm, 3.5 μm) yielded optimal
column efﬁciency and peak shape for the compounds. The drug and
the internal standard could be separated ideally in all three columns
under the acetonitrile ratios between 20% and 30%. Further, we
intended to set retention time of the drug peak longer than 2.0 min in
order to avoid interference from these polar endogenous metabolites
which might cause interfering ion suppression or enhancement to the
drug ion. Finally, the acetonitrile–water (0.1% formic acid) (23:77,
v/v) was set as the mobile phase composition.
To achieve the higher signal response, both positive and negative scan
modes were investigated. The results showed that the target molecule
could give better ion intensity in the negative mode than in the positive
mode. Based on the chemical structures showed in Fig. 1, we supposed
that this ﬂavane tends to dissociate and gives several neutral losses due to
its galloyl and hydroxyl groups in the positive mode after protonation. In
contrast, this ﬂavane maintained stability after deprotonation in negative
mode due to the existence of the conjugated system and electron-
donating groups. In this condition, IS could be ionized efﬁciently as well.
In full-scan mass spectra, J10688 and IS predominantly formed [M–H]–
ions at m/z 441.0 and m/z 301.0, respectively (Fig. 2).sample; (B) blank rat plasma sample spiked with J10688 (10 ng/mL)
ction of 10 mg/kg J10688 spiked with IS (50 ng/mL).
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3.2.1. Speciﬁcity
The speciﬁcity of the method was evaluated by comparing the
chromatograms of blank plasma, plasma sample spiked with
J10688 and IS, and a real rat plasma sample obtained 20 min
after intravenous administration of J10688 at 10 mg/kg (Fig. 3).
No endogenous or other interfering peaks were observed from
plasma at the retention time of J10688 and IS, indicating that the
method was speciﬁc.3.2.2. Linearity and LLOQ
Each calibration curve was constructed by plotting the peak area
ratios (y) of the analyte (J10688) to the IS versus the nominal
concentration (x) of the analyte (10–2000 ng/mL for J10688).Table 3 Stability of J10688 in rat plasma.
Condition Spiked conc. (ng/mL)
Three freeze/thaw cycles 50
250
1500
Short-term (25 1C for 4 h) 50
250
1500
Autosampler for 24 h (25 1C) 50
250
1500
Long-term (40 1C for four weeks) 50
250
1500
aData are expressed as mean7SD, n ¼5.
Table 2 Recovery and matrix effect of J10688 and IS in rat
plasma (n ¼5).
Analyte Spiked conc.
(ng/mL)
Recovery (%) Matrix effect
(%)
J10688 50 102.91 99.13
250 102.44 96.42
1500 99.65 97.12
IS 500 72.19 91.94
Table 1 Intra- and inter-day precision and accuracy of
J10688 in the rat plasma.
Spiked
conc.
(ng/mL)
Measured
concentration
(ng/mL)a
RE (%) RSD
(%)
Intra-day 50 53.6471.39 107.27 2.59
250 251.6775.26 100.67 2.09
1500 1502.19716.49 100.15 1.10
Inter-day 50 53.2174.24 106.42 7.98
250 251.7879.37 100.71 3.72
1500 1505.57750.34 100.37 3.34
aData are expressed as mean7SD, n ¼5.The calibration curve showed good linearity over the plasma
concentration with correlation coefﬁcients (r) ranging from 0.9993
to 0.9999. The LLOQ, deﬁned as the lowest concentration
detected, was 10 ng/mL with an RSD of 2.07% for J10688 in
rat plasma. Accuracy was within 720%, precision was r20%.
These results conﬁrmed that the method was sensitive enough for
the pharmacokinetic study of J10688 in rats.3.2.3. Accuracy and precision
The intra- and inter-day precision and accuracy were calculated by
analyzing three concentration levels of QC samples. The results
are exhibited in Table 1. The intra- and inter-day precision for
J10688 was less than 7.98%, and the accuracy for J10688 was
within 100.15% and 107.27%, respectively. These results indi-
cated that the method was precise and accurate for determination
of J10688 and IS in rat plasma.3.2.4. Extraction recovery and matrix effect
The extraction recovery and matrix effect were evaluated by
determining QC samples at 50, 250 and 1500 ng/mL with ﬁve
replicates. Data are shown in Table 2. The extraction recoveries of
J10688 at three concentration levels ranged from 99.65% to
102.91% and the IS value was 72.19%. The matrix effect values
for the analyte J10688 were 99.13%, 96.42% and 97.12% for the
three QC concentration samples, respectively. These data demon-
strate that acetonitrile is an appropriate and feasible medium for
J10688 and IS extraction. No signiﬁcant ion suppression or
enhancement from plasma matrix was observed under the present
experimental conditions.3.2.5. Stability
To test the possible effect of all experienced conditions for
samples. QC samples of three concentrations (50, 250 and
1500 ng/mL) were stored under different conditions, including
sample handling, processing and analysis. The results were
presented in Table 3, indicating that the samples were stable for
4 h at 25 1C and 24 h in the autosampler (25 1C), and no
signiﬁcant degradation occurred after three freeze-thaw cycles
and long term storage (–40 1C for four weeks). The RSD (%)
values were less than 6.75% for all QC samples, which demon-
strated the reproducibility of this method for J10688.Measured conc. (ng/mL)a RSD (%) RE (%)
50.0470.54 1.07 100.08
252.75711.50 4.55 101.10
1481.97729.58 2.00 98.80
51.2970.43 0.84 102.58
257.0573.52 1.37 102.82
1489728.88 1.94 99.27
46.772.87 6.15 93.40
253.0275.09 2.01 101.21
1520.68724.80 1.63 101.33
50.1673.38 6.75 100.32
246.43713.53 5.49 98.57
1469.50753.41 3.63 97.97
Figure 4 Mean plasma concentration-time curves of J10688 in rats. (A) Mean plasma concentration-time curves of J10688 (i.v., n ¼6);
(B) semi-logarithmic axis mean plasma concentration-time curves of J10688 (i.v., n ¼6).
Table 4 Pharmacokinetic parameters of J10688 after intravenous administration in rat.
Parameter Unit J10688 (mg/kg)a
10 3 1
AUC0–t μg  h/L 11,806.6271651.11 3678.64871235 1752.297538.72
AUC0–1 μg  h/L 11,929.6371536.63 3773.39571223.312 1788.6947533.7
MRT0–t h 0.36670.122 0.28370.083 0.21770.062
MRT0–1 h 0.45270.159 0.49570.339 0.27570.094
t1/2 h 1.31670.884 1.61971.268 0.52670.123
Vd L/kg 1.66971.19 2.12872.151 0.45770.161
CL L  kg/h 0.8570.112 0.86470.265 0.60770.195
C0 μg/L 50,827.117717151.46 19,528.178253.442 11,264.78374684.666
aData are expressed as mean7SD, n ¼6.
Table 5 Assessment of dose proportionality of J10688 based
on power model.
Parameter Acceptance range β1 90% Conﬁdence
interval
AUC0–t 0.9031–1.0969 0.8456 0.7204–0.9708
AUC0–1 0.9031–1.0969 0.8407 0.7206–0.9608
C0 0.8451–1.155 0.6752 0.5083–0.8422
β1: the slopes of lnAUC0–t, lnAUC0–1 and lnC0 to lnDose.
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The presently developed LC–MS method was successfully
applied to the pharmacokinetic study of J10688 in rats.
Plasma drug concentration-time curves of J10688 were
obtained after three different i.v. doses. The results are
displayed in Fig. 4. The main pharmacokinetic parameters
of J10688 were calculated by a non-compartment model
analysis (Table 4). After injection of J10688, it was rapidly
distributed in the blood. Time for half-life elimination (t1/2)
was 1.32, 1.62 and 0.53 h, respectively, indicating that
J10688 was relatively quickly eliminated from plasma with
a short elimination half-life. The maximum plasma drug
concentration (C0) of J10688 ranged from 11.26–50.83 g/L,
and values of AUC0–t were 11806.6271651.11, 3678.6487
1235 and 1752.297538.72 μg  h/L, respectively.
Dose proportionality was assessed using the power model in a
manner analogous to a published method15,16. Dose correlation results
showed that, in doses ranging from 1 to 10 mg/kg, the slopes (β1) of
ln(AUC0–t), ln(AUC0–1) and ln(C0) to ln(dose) were 0.8456, 0.8407
and 0.6752，respectively (Table 5). According to the power
model17,18, 90% conﬁdence intervals were 0.7204–0.9708 for
AUC0–t, 0.7206–0.9608 for AUC0–1, and 0.5083–0.8422 for C0,
which were out of the range 0.9031–1.0969 and 0.8451–1.155. The
relationships between ln (Exposure) and ln (Dose) are shown in Fig. 5.
The regression analysis indicated less perfect linearity of the kinetics of
J10688 after intravenous administration.J10688 showed relatively quick elimination rates in rat after
tail vein injection. The drug disappeared completely 6 h after
the high dose (10 mg/kg) after 2 h after the low (1 mg/kg) dose.
The pharmacokinetic parameters showed that the exposure level
(characterized with AUC) correlated with certain doses, and the
dose of 10 mg/kg J10688 demonstrated non-linearity with
pharmacokinetics parameters. It is likely that this high dose
exceeds maximum capacity of a drug metabolic or transporter
mechanism. When speciﬁc transporters or the metabolic
enzymes become saturated due to the high drug concentration
level, biochemical elimination processes like active transport in
kidney tubules or phase I/II metabolism slow down19–21. Unlike
the case for ﬁrst-order kinetic processes, the pharmacokinetic
parameters of J10688 (half-life and clearance) are not constant,
but varied with different doses. Consistent with this conclusion,
the AUC and C0 values were not proportional to dose. All of
Figure 5 Relationship between lnPK and lnDose. (A): AUC0–t; (B): AUC0–1; (C): C0. The blank dots are the individual observed values; the full
lines are the ﬁtted values calculated by the power model and the dotted lines are the 90% conﬁdence interval.
Chao Li et al.70these patterns indicate the existence of non-linear pharmacoki-
netic processes for J10688.4. Conclusions
This study is the ﬁrst to evaluate the pharmacokinetics of galloca-
techin-7-gallate, an active anti-inﬂuenza virus candidate isolated from
P. clypearia. A sensitive, rapid and reliable LC–MS method was
developed to analyze J10688 in rat plasma. The established method
was successfully applied to the pharmacokinetic study of J10688 in
SD rats following i.v. administration of three doses. These results will
provide more information about the pharmacokinetic proﬁles of
J10688 for its subsequent preclinical studies and guide the pharma-
cokinetic study of structurally similar compounds.
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